New bladder cancer drug delivery system tested in small japanese study

NCT ID NCT05567185

Ongoing Disease control Sponsor: Janssen Pharmaceutical K.K. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is safe and tolerable, and to measure how much of the drug gets into the blood and urine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Apert syndrome non-invasive bladder urothelial carcinoma urinary bladder neoplasm Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECEPTORS, FIBROBLAST GROWTH FACTOR URINARY BLADDER NEOPLASMS

Contacts and locations

Show contact details

Locations

Osaka International Cancer Institute

Osaka, 541 8567, Japan
St Marianna University Hospital

Kanagawa, 216 8511, Japan
Toyama University Hospital

Toyama, 930-0194, Japan
University of Tsukuba Hospital

Tsukuba, 305 8576, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.